248 related articles for article (PubMed ID: 32909077)
1. Immune checkpoint-related serum proteins and genetic variants predict outcomes of localized prostate cancer, a cohort study.
Wang Q; Ye Y; Yu H; Lin SH; Tu H; Liang D; Chang DW; Huang M; Wu X
Cancer Immunol Immunother; 2021 Mar; 70(3):701-712. PubMed ID: 32909077
[TBL] [Abstract][Full Text] [Related]
2. Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients.
Wang Q; Zhang J; Tu H; Liang D; Chang DW; Ye Y; Wu X
J Immunother Cancer; 2019 Nov; 7(1):334. PubMed ID: 31783776
[TBL] [Abstract][Full Text] [Related]
3. Peripheral Soluble Immune Checkpoint-Related Proteins Were Associated with Survival and Treatment Efficacy of Osteosarcoma Patients, a Cohort Study.
Li B; Wang Q; Luo Y; Wang S; Pan S; Zhao W; Ye Z; Wu X
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730580
[TBL] [Abstract][Full Text] [Related]
4. Soluble Immune Checkpoint-Related Proteins in Blood Are Associated With Invasion and Progression in Non-Small Cell Lung Cancer.
Wang Q; He Y; Li W; Xu X; Hu Q; Bian Z; Xu A; Tu H; Wu M; Wu X
Front Immunol; 2022; 13():887916. PubMed ID: 35874720
[TBL] [Abstract][Full Text] [Related]
5. Genetic variants in epithelial-mesenchymal transition genes as predictors of clinical outcomes in localized prostate cancer.
Deng Y; Xie K; Logothetis CJ; Thompson TC; Kim J; Huang M; Chang DW; Gu J; Wu X; Ye Y
Carcinogenesis; 2020 Aug; 41(8):1057-1064. PubMed ID: 32215555
[TBL] [Abstract][Full Text] [Related]
6. Genetic variants in the TEP1 gene are associated with prostate cancer risk and recurrence.
Gu C; Li Q; Zhu Y; Qu Y; Zhang G; Wang M; Yang Y; Wang J; Jin L; Wei Q; Ye D
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):310-6. PubMed ID: 26238235
[TBL] [Abstract][Full Text] [Related]
7. The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer.
Gevensleben H; Dietrich D; Golletz C; Steiner S; Jung M; Thiesler T; Majores M; Stein J; Uhl B; Müller S; Ellinger J; Stephan C; Jung K; Brossart P; Kristiansen G
Clin Cancer Res; 2016 Apr; 22(8):1969-77. PubMed ID: 26573597
[TBL] [Abstract][Full Text] [Related]
8. Effect of genetic variants in cell adhesion pathways on the biochemical recurrence in prostate cancer patients with radical prostatectomy.
Yu CC; Chen LC; Lin VC; Huang CY; Cheng WC; Hsieh AR; Chang TY; Lu TL; Lee CH; Huang SP; Bao BY
Cancer Med; 2019 Jun; 8(6):2777-2783. PubMed ID: 30993852
[TBL] [Abstract][Full Text] [Related]
9. Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort.
Wang Q; Gregg JR; Gu J; Ye Y; Chang DW; Davis JW; Thompson TC; Kim J; Logothetis CJ; Wu X
Oncoimmunology; 2019; 8(1):e1483303. PubMed ID: 30546938
[TBL] [Abstract][Full Text] [Related]
10. A single nucleotide polymorphism in ADIPOQ predicts biochemical recurrence after radical prostatectomy in localized prostate cancer.
Gu C; Qu Y; Zhang G; Sun L; Zhu Y; Ye D
Oncotarget; 2015 Oct; 6(31):32205-11. PubMed ID: 26320190
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Significance of Immune Checkpoints HLA-G/ILT-2/4 and PD-L1 in Colorectal Cancer.
Chen QY; Chen YX; Han QY; Zhang JG; Zhou WJ; Zhang X; Ye YH; Yan WH; Lin A
Front Immunol; 2021; 12():679090. PubMed ID: 34054869
[TBL] [Abstract][Full Text] [Related]
12. Genetic variants in the Hippo pathway predict biochemical recurrence after radical prostatectomy for localized prostate cancer.
Huang CY; Huang SP; Lin VC; Yu CC; Chang TY; Juang SH; Bao BY
Sci Rep; 2015 Feb; 5():8556. PubMed ID: 25707771
[TBL] [Abstract][Full Text] [Related]
13. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
[TBL] [Abstract][Full Text] [Related]
14. rs4143815-
Zanusso C; Dreussi E; Bortolus R; Romualdi C; Gagno S; De Mattia E; Romanato L; Sartor F; Quartuccio L; Cecchin E; Toffoli G
Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31035590
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of immune checkpoint molecules in breast cancer.
Fang J; Chen F; Liu D; Gu F; Chen Z; Wang Y
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32602545
[TBL] [Abstract][Full Text] [Related]
16. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.
Gevensleben H; Holmes EE; Goltz D; Dietrich J; Sailer V; Ellinger J; Dietrich D; Kristiansen G
Oncotarget; 2016 Nov; 7(48):79943-79955. PubMed ID: 27835597
[TBL] [Abstract][Full Text] [Related]
18. Soluble immune checkpoint molecules in patients with antineutrophil cytoplasmic antibody-associated vasculitis.
Pyo JY; Yoon T; Ahn SS; Song JJ; Park YB; Lee SW
Sci Rep; 2022 Dec; 12(1):21319. PubMed ID: 36494415
[TBL] [Abstract][Full Text] [Related]
19. Prediction of risk and overall survival of pancreatic cancer from blood soluble immune checkpoint-related proteins.
Pan S; Zhao W; Li Y; Ying Z; Luo Y; Wang Q; Li X; Lu W; Dong X; Wu Y; Wu X
Front Immunol; 2023; 14():1189161. PubMed ID: 37256126
[TBL] [Abstract][Full Text] [Related]
20. Leukocyte telomere length is associated with aggressive prostate cancer in localized prostate cancer patients.
Xu J; Chang WS; Tsai CW; Bau DT; Xu Y; Davis JW; Thompson TC; Logothetis CJ; Gu J
EBioMedicine; 2020 Feb; 52():102616. PubMed ID: 31981976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
